At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients With Tumors With Deleterious PTEN Sequencing Result and PTEN Expression by IHC
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 3 other interventions for Advanced Lymphoma and 4 related conditions. Active but no longer recruiting, targeting 35 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial tests how well copanlisib works in treating patients with cancer that has certain genetic changes. Copanlisib is used in patients whose cancer has a mutated (changed) form of a gene called PTEN. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Study Details
Timeline
Interventions
Undergo biopsy
Undergo blood sample collection
Undergo CT scan
Given IV
Undergo MRI